Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases

被引：0
|
作者：
Costa, Luis
Fizazi, Karim
Saad, Fred
Brown, Janet Elizabeth
Von Moos, Roger
Oudard, Stephane
Sternberg, Cora N.
Ganju, Vinod
Miller, Kurt
Wang, Huei
Maniar, Tapan
Braun, Ada
机构：
[1] Hosp Santa Maria, Lisbon, Portugal
[2] Inst Med Mol, Lisbon, Portugal
[3] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France
[4] Univ Montreal Hosp Ctr, CRCHUM, Montreal, PQ, Canada
[5] Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[6] Kantonsspital Graubunden, Chur, Switzerland
[7] Georges Pompidou European Hosp, Paris, France
[8] San Camillo Forlanini Hosp, Rome, Italy
[9] Peninsula Oncol Ctr, Frankston, Australia
[10] Charite, D-13353 Berlin, Germany
[11] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5079
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Denosumab and zoledronic acid (ZA) treatment in patients with genitourinary (GU) cancers and bone metastases
    Ganju, Vinod
    Costa, Luis
    Fizazi, Karim
    Saad, Fred
    Brown, Janet
    von Moos, Roger
    Oudard, Stephane
    Sternberg, Cora N.
    Miller, Kurt
    Wang, Huei
    Maniar, Tap
    Braun, Ada
    BJU INTERNATIONAL, 2013, 112 : 11 - 11
  • [2] Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers
    Saad, F
    Lipton, A
    BJU INTERNATIONAL, 2005, 96 (07) : 964 - 969
  • [3] Breast cancer bone metastases: denosumab or zoledronic acid?
    Gabri van der Pluijm
    Nature Reviews Endocrinology, 2011, 7 : 134 - 135
  • [4] Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid
    Aapro, Matti
    Saad, Fred
    THERAPEUTIC ADVANCES IN UROLOGY, 2012, 4 (02) : 85 - 101
  • [5] CANCER Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm, Gabri
    NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (03) : 134 - 135
  • [6] Recommendations for zoledronic acid treatment of patients with bone metastases
    Berenson, JR
    ONCOLOGIST, 2005, 10 (01): : 52 - 62
  • [7] Financial impact of coverage for zoledronic acid and denosumab in cancer patients with bone metastases.
    Russell, M. W.
    Bell, M. J.
    Namjoshi, M.
    Miller, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours
    Zheng, G. Z.
    Chang, B.
    Lin, F. X.
    Xie, D.
    Hu, Q. X.
    Yu, G. Y.
    Du, S. X.
    Li, X. D.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [9] Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases
    Koo, Kaitlin
    Lam, Kinsey
    Mittmann, Nicole
    Konski, Andre
    Dennis, Kristopher
    Zeng, Liang
    Lam, Henry
    Chow, Edward
    SUPPORTIVE CARE IN CANCER, 2013, 21 (06) : 1785 - 1791
  • [10] Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases
    Kaitlin Koo
    Kinsey Lam
    Nicole Mittmann
    Andre Konski
    Kristopher Dennis
    Liang Zeng
    Henry Lam
    Edward Chow
    Supportive Care in Cancer, 2013, 21 : 1785 - 1791
12345